Answers are grounded in this paper and cite their sources.
BACKGROUND: As a rapidly developing therapeutic method, targeted therapy plays an important role in the treatment of multiple myeloma. In recent years, mature B cell antigen-targeting therapy has brought new hope for patients with refractory/relapsed disease. While an increasing number of patients with relapse are exposed to this type of drug, changing the therapeutic target may be an effective strategy for patients with relapse/refractory multiple myeloma. OBJECTIVES: The expression of G protein-coupled receptor, class C Group 5 member D (GPRC5D), on the surface of myeloma tumor cells makes it a possible target for relapse/refractory multiple myeloma therapy, and relevant studies are in progress. RESULTS & CONCLUSIONS: The review aims to systematically summarize the current advancements in GPRC5D-targeted therapies for multiple myeloma, thereby providing valuable insights and a foundation for future studies.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: